Vancomycin use in patients requiring hemodialysis: A literature review

Seminars in Dialysis

Volumn 21, Issue 1, 2008, Pages 63-70

  Pallotta, Katie E ^a   Manley, Harold J ^a,b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b Albany Nephrology Pharmacy ANephRx Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; VANCOMYCIN;

ARTICLE; CROSS INFECTION; DRUG EFFECT; HUMAN; PENICILLIN RESISTANCE; RENAL REPLACEMENT THERAPY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; HUMANS; METHICILLIN RESISTANCE; RENAL DIALYSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 38749088318     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2007.00333.x     Document Type: Article

References (53)

1. Manley HJ, Huke MA, Dykstra MA, Bedenbaugh AV : Antibiotic prescribing evaluation in an outpatient hemodialysis clinic. J Pharm Technology 18 : 128 132, 2002
2. American Pharmaceutical Partners : Vancomycin Package Insert. Schaumberg, IL, 2003.
3. United States Renal Data System : USRDS 2005 Annual Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD : National Institutes of Health, The National Institute of Diabetes and Digestive and Kidney Diseases, 2005.
4. Tokars JI, Miller ER, Stein G : New national surveillance system for hemodialysis-associated infections: initial results. Am J Infect Control 30 : 288 295, 2002
5. Centers for Disease Control Prevention : Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Morb Mortal Wkly Rep 44 : 3 4, 1995
6. Centers for Disease Control Prevention : Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin resistance. MMWR Morb Mortal Wkly Rep 46 : 626 628, 1997
7. Green K, Schulman G, Haas DW, Schaffner W, D'Agata EMC : Vancomycin prescribing practices in hospitalized chronic hemodialysis patients. Am J Kidney Dis 35 : 64 68, 2000
8. Centers for Disease Control Prevention : Staphylococcus aureus resistant to Vancomycin - United States, 2002. MMWR Morb Mortal Wkly Rep 51 : 565 567, 2002
9. DeSoi CA, Sahm DF, Umans JG : Vancomycin elimination during high-flux hemodialysis: kinetic model and comparison of four membranes. Am J Kidney Dis 20 : 354 360, 1992
10. Lindholm DD, Murray JS : Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis. N Engl J Med 274 : 1047 1051, 1966
11. Matzke GR, McGory RW, Halstenson CE, Keane WF : Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 25 : 433 437, 1984
12. Tokars JI, Miller ER, Alter MJ, Ardino MJ : National surveillance of dialysis-associated diseases in the United States. Centers for Disease Control and Prevention, 1997. Semin Dial 13 : 75 85, 2000
13. Lanese DM, Alfrey PS, Molitoris BA : Markedly increased clearance of vancomycin during hemodialysis using polysulfone dialyzers. Kidney Int 35 : 1409 1412, 1989
14. Torras J, Cao C, Rivas MC, Cano M, Fernandez E, Montoliu J : Pharmacokinetics of vancomycin in patients undergoing hemodialysis with polyacrylonitrile. Clin Nephrol 36 : 35 41, 1991
15. Quale JM, O'Halloran JJ, DeVincenzo N, Barth RH : Removal of vancomycin by high-flux hemodialysis membranes. Antimicrob Agents Chemother 36 : 1424 1426, 1992
16. Welage LS, Mason NA, Hoffman EJ, Odeh RM, Dombrouski J, Patel JA, Swartz RD : Influence of cellulose triacetate hemodialyzers on vancomycin pharmacokinetics. J Am Soc Nephrol 6 : 1284 1290, 1995
17. Zoer J, Schrander-van der Meer AM, van Dorp WT : Dosage recommendation of vancomycin during haemodialysis with highly permeable membranes. Pharm World Sci 19 : 191 196, 1997
18. Scott MK, Macias WL, Kraus MA, Clark WR, Carfagna MA, Mueller BA : Effects of dialysis membrane on intradialytic vancomycin administration. Pharmacotherapy 17 : 256 262, 1997
19. Foote EF, Dreitlein WB, Steward CA, Kapoian T, Walker JA, Sherman RA : Pharmacokinetics of vancomycin when administered during high flux hemodialysis. Clin Nephrol 50 : 51 55, 1998
20. Mason NA, Neudeck BL, Welage LS, Patel JA, Swartz RD : Comparison of 3 vancomycin dosage regimens during hemodialysis with cellulose triacetate dialyzers: post-dialysis versus intradialytic administration. Clin Nephrol 60 : 96 104, 2003
21. Ariano RE, Fine A, Sitar DS, Rexrode S, Zelenitsky SA : Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis. Am J Kidney Dis 46 : 681 687, 2005
22. Pai AB, Pai MP : Vancomycin dosing in high flux hemodialysis: a limited-sampling algorithm. Am J Health Syst Pharm 61 : 1812 1816, 2004
23. Nyman HA, Agarwal A, Senekjian HO, Gilson J, Cheung AK, Leypoldt JK : Dosing Vancomycin During High-Flux Hemodialysis. St. Louis, MO : Annual Meeting of the American College of Clinical Pharmacists, 2006
24. Pollard TA, Lampasona V, Akkerman S, Tom K, Hooks MA, Mullins RE, Maroni BJ : Vancomycin redistribution: dosing recommendations following high-flux hemodialysis. Kidney Int 45 : 232 237, 1994
25. Touchette MA, Patel RV, Anandan JV, Dumler F, Zarowitz BJ : Vancomycin removal by high-flux polysulfone hemodialysis membranes in critically ill patients with end-stage renal disease. Am J Kidney Dis 26 : 469 474, 1995
26. Hemodialysis Adequacy 2006 Work Group : Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis 48 : S2 S90, 2006
27. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ : National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 18 : 52 61, 2005
28. Scott MK, Mueller BA, Sowinski KM : The effects of peracetic acid-hydrogen peroxide reprocessing on dialyzer solute and water permeability. Pharmacotherapy 19 : 1042 1049, 1999
29. Scott MK, Mueller BA, Sowinski KM, Clark WR : Dialyzer-dependent changes in solute and water permeability with bleach processing. Am J Kidney Dis 33 : 87 96, 1999
30. US Preventive Services Task Force : Screening for obesity in adults: recommendations and rationale. Ann Intern Med 139 : 930 932, 2003
31. Karam CM, McKinnon PS, Neuhauser MM, Rybak MJ : Outcome assessment of minimizing vancomycin monitoring and dosing adjustments. Pharmacotherapy 19 : 257 266, 1999
32. Bauer LA, Black DJ, Lill JS : Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 54 : 621 625, 1998
33. Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO : Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 21 : 575 580, 1982
34. Penzak SR, Gubbins PO, Rodvold KA, Hickerson SL : Therapeutic drug monitoring of vancomycin in a morbidly obese patient. Ther Drug Monit 20 : 261 265, 1998
35. Moellering RC, Krogstad DJ, Greenblatt DJ : Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Int Med 94 : 343 346, 1981
36. Cantú TG, Yamanaka-Yuen NA, Lietman PS : Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 18 : 533 548, 1994
37. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171 : 388 416, 2005
38. Hu MW, Anne L, Forni T, Gottwald K : Measurement of vancomycin in renally impaired patient samples using a new high-performance liquid chromatography method with vitamin B12 internal standard: comparison of high-performance liquid chromatography, EMIT, and fluorescence polarization immunoassay methods. Ther Drug Monit 12 : 562 569, 1990
39. Abbott Laboratories : TDx/TDxFLx Vancomycin Assay Package Insert. Abbott Park, IL : Abbott Laboratories, 2005
40. Abbott Laboratories : AxSYM Vancomycin II Assay Package Insert. Abbott Park, IL : Abbott Laboratories, 2005
41. Somerville AL, Wright DH, Rotschafer JC : Implications of vancomycin degradation products in therapeutic drug monitoring in patients with end-stage renal disease. Pharmacotherapy 19 : 702 707, 1999
42. Morse GD, Nairn DK, Bertino JS, Walshe JJ : Overestimation of vancomycin concentrations utilizing fluorescence polarization immunoassay in patients on peritoneal dialysis. Ther Drug Monit 9 : 212 215, 1987
43. Peckman HJ, Dupuis RE, Sawyer WT, Brouwer KLR, Cross RE : Vancomycin serum concentrations in patients with renal dysfunction: a comparison of fluorescence polarization immunoassay and the enzyme-multiplied immunoassay technique. Ther Drug Monit 18 : 647 653, 1996
44. Sym D, Smith C, Meenan G, Lehrer M : Fluorescence polarization immunoassay: can it result in an overestimation of vancomycin in patients not suffering from renal failure? Ther Drug Monit 23 : 441 444, 2001
45. Kingery JR, Sowinski KM, Kraus MA, Klaunig KE, Mueller BA : Vancomycin assay performance in patients with end-stage renal disease receiving hemodialysis. Pharmacotherapy 20 : 653 656, 2000
46. Hammett-Stabler CA, Johns T : Laboratory guidelines for monitoring antimicrobial drugs. Clin Chem 44 : 1129 1140, 1998
47. Wilson JF, Davis AC, Tobin CM : Evaluation of commercial assays for vancomycin and aminoglycosides in serum: a comparison of accuracy and precision based on external quality assessment. J Antimicrob Chemother 52 : 78 82, 2003
48. Wazny LD, Daghigh B : Desensitization protocols for vancomycin hypersensitivity. Ann Pharmacother 35 : 1458 1464, 2001
49. Rybak MJ, Bailey EM, Warbasse LH : Absence of "red man syndrome" in patients being treated with vancomycin or high-dose teicoplanin. Antimicrob Agents Chemother 36 : 1204 1207, 1992
50. Healy DP, Sahai JV, Fuller SH, Polk R : Vancomycin-induced histamine release and "red man syndrome": comparison of 1 and 2 hour infusions. Antimicrob Agents Chemother 34 : 550 554, 1990
51. Traber PG, Levine DP : Vancomycin ototoxicity in a patient with normal renal function. Ann Intern Med 95 : 458 460, 1981
52. Klibanov OM, Filicko JE, DeSimone JA Jr., Tice DS : Sensorineural hearing loss associated with intrathecal vancomycin. Ann Pharmacother 37 : 61 65, 2003
53. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL : Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 43 : 1549 1555, 1999